Japanese recommendation takes Sanwa's anagliptin closer to first market
This article was originally published in Scrip
Executive Summary
Sanwa Kagaku Kenkyusho/Kowa's anagliptin (SK-0403) has moved a step closer to becoming the sixth DPP-4 inhibitor to be launched in Japan following a positive approval recommendation for the treatment of type 2 diabetes.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Need a specific report? 1000+ reports available
Buy Reports